Inclusion of existing biobanks and biobanks consisting of biomaterial left-overs in the Radboud Biobank

The Board of Directors has decided to transfer all existing collections of biomaterials to the Radboud Biobank unless explicitly decided otherwise. This also pertains to biomaterials obtained during clinical care from which remaining material is presented for research purposes, and biomaterials left over from past research projects.

Background

The Radboud Biobank facilitates the storage and issuance of biomaterial and clinical data from prospective 'de novo' biobanks comprised of Radboudumc patients who have provided written informed consent for the collection and use of biomaterial in scientific medical research.
The inclusion of existing biobanks and historical collections in the Radboud Biobank improves the quality of the existing biobank by aligning with Radboud Biobank standards and further increases the visibility of the existing biobank. Such measures greatly increase the value of the existing biobank. The Radboud Biobank also offers departments, heath care chains, and consortia that retain biomaterial left-overs the opportunity to join the as a sub-biobank.

Conditions for joining the Radboud Biobank

1. Clear description of the potential scientific value of the biomaterials;
2. (Application for) approval for the existing biobank from the CMO(-light). The CMO(-light) verifies if legal-ethical demands have been met (only biomaterial and data collected as part of routine health care, patients have been informed; there is the opportunity to opt-out and opt-out requests are noted and processed);
3. Biomaterial and data are linked by a code to a unique (ex)patient from the Radboudumc using an encrypted key file;
4. Biomaterials are stored suitable for future research. Collection date plus relevant conditions are recorded.
5. As a minimum: age, sex, initial diagnosis code and unique patient number are recorded.
6. A signed contract between the sub-biobank and the Radboud Biobank with standard terms and conditions regarding personnel investments, right-of-say, issuance and financial arrangements.

Consequences for the storage of the biomaterial

The collection is included in the biobank management system with new codes and notes regarding prior storage conditions. To avoid unnecessary defrosting and refreezing refill to Radboud Biobank storage standards is done when an opportunity occurs, e.g. at the occasion of the first issuance. Processing dates are recorded in biobank tracking system.

Financial consequences

Repacking and moving biomaterial and data from the sub-biobank to the Radboud Biobank is at the expense of the sub-biobank, ad offered by the Radboud Biobank (see appendix 1). Taking into consideration that the costs incurred during the preliminary phase were not covered by the Radboud Biobank, these costs will not be included in the Radboud Biobank rates. Adapted prices for issuances will be charged to the sub-biobank to cover the costs of storage and management. For external issuances the sub-biobank may set additional arrangements.

Appendix 1 – Define nature of existing collection

Clinical data

1. Has clinical data been collected?
2. In what system is clinical data collected?
3. Name of the contact person concerning the clinical data.

Biomaterial

Type of biomaterial	Number of patients	Number of measurement points	Number of samples	Exact location[#]	How is the location recorded[*]	Remarks

E.g. -80°C freezer at the department

* E.g. in a biobank management system or in Excel

Name of the contact person concerning the biomaterial.